As a clinical-stage biotech with no revenue, the key catalysts are pipeline milestones and regulatory updates. Monitor for upcoming data readouts or partnership announcements, as these are the primary drivers for the stock. The current cash position provides a runway into 2027, reducing near-term financing risk.
SPRO drugs
SPRO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 13 $1.24entry
- T+1 · 3mo ago −0.81%α −0.61% · $1.23
- T+5 · 3mo ago −1.61%α +0.35% · $1.22
- T+20 · 2mo ago −8.87%α −7.12% · $1.13
- T+60 · 11d ago −16.94%α −11.46% · $1.03
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spero Therapeutics reported Q2 2026 financial results, highlighting a net loss of $11.0 million for the quarter, compared to a net loss of $10.7 million in the same period last year. The company ended the quarter with $60.7 million in cash, cash equivalents, and marketable securities, providing a runway into 2027. The results are largely neutral for a clinical-stage biotech with no approved products, as the focus remains on pipeline development rather than financial performance.
Key Financial Metrics
Key Facts
- Net loss of $11.0 million for Q2 2026, compared to $10.7 million in Q2 2025.
- Cash, cash equivalents, and marketable securities of $60.7 million as of June 30, 2026.
- Research and development expenses were $7.5 million for Q2 2026, down from $8.5 million in Q2 2025.
- General and administrative expenses were $4.2 million for Q2 2026, compared to $4.0 million in Q2 2025.
- No revenue was reported for the quarter, consistent with the company's clinical-stage status.
Financial Impact
Net loss of $11.0 million, with cash runway into 2027.
Risk Factors
- Clinical trial failures or delays could significantly impact the stock.
- Need for future capital raises to fund operations beyond current cash runway.
- No approved products or revenue streams, making the company entirely dependent on pipeline success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344036 |
Track record
17 reports on SPRO
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
- Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
- Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 12, 202613w ago Press Release Neutral 4/10 Viewing Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
- Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
- Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers